From the PR - the key is this news.
Can we get this news before year end?
Will it be positive? If not, it will rank.
In reality, this is not a Covid play and no valuation is included in current price but bad news impacts the SP anyways.
In fact, for the severe Covid cases, there are only handful drugs that actually are under trial at late stage - RDHL, CYDY, MRK, HGEN and RLFTF
However, CYDY is ahead of everyone as the enrollment is complete and P3 results expected by last week of Jan
MRK P3 enrollment is going on and RDHL P2/3 enrollment is going on.
“Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib”
Market Data 
Markets 
AI
